Intra-cellular Therapies, Inc.

This study tested a long-acting injectable (LAI) form of the drug lumateperone in 52 adults with stable schizophrenia or schizoaffective disorder. Participants received a single injection of one of several LAI formulations, along with oral capsules, to see how the drug behaves in…

This study tested a drug called lenrispodun in 79 people with Parkinson's disease who experience 'wearing off' symptoms and involuntary movements. Participants took the drug or a placebo once daily alongside their usual treatment. The goal was to see if lenrispodun could improve …

This study tested an experimental drug called ITI-007 in 696 adults with schizophrenia who were having a sudden worsening of symptoms. Participants received either ITI-007, a placebo, or an active comparator (risperidone) for 6 weeks. The main goal was to see if ITI-007 reduces s…

This study tested the safety and tolerability of lumateperone, an antipsychotic drug, in 26 adolescents aged 13 to 17 with schizophrenia or schizoaffective disorder. Participants took either 28 mg or 42 mg of lumateperone by mouth. Researchers measured how the drug moves through …

This study looked at the safety of adding lumateperone to standard antidepressants for people with major depressive disorder. Over 800 adults who completed earlier studies took the drug for 26 weeks. The main goal was to track side effects, with a focus on how well people tolerat…

This study tested a new medication, lumateperone, to see if it can safely ease depression in people with bipolar I or II disorder. Over 550 adults took either the drug or a placebo for six weeks. Researchers measured changes in depression symptoms using a standard rating scale.

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia during an acute psychotic episode. 335 adults with schizophrenia were randomly assigned to receive ITI-007, a placebo, or an active control for 28 days. The main goal was to measure changes i…

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia better than a placebo. About 450 adults with schizophrenia who were having a sudden worsening of symptoms took part. The main goal was to see if their symptoms improved after 28 days of treat…

This early-stage study tested the safety and tolerability of a new drug called ITI-333 in 32 healthy adults aged 18 to 45. Participants received either the drug or a placebo once daily for 14 days. The goal was to measure how the drug moves through the body and check for any side…

This early-stage study tested a single dose of the experimental drug ITI-333 in 12 healthy adults. Researchers used brain scans to see how much of the drug attached to a specific receptor (5-HT2A) in the brain. They also checked safety, side effects, and how the drug moves throug…